HLA-DRB1: A Drug Target / Disease Biomarker (G3123)

Target Name: HLA-DRB1

NCBI ID: G3123

HLA-DRB1: A Drug Target / Disease Biomarker

HLA-DRB1 is a human leukocyte antigen (HLA) gene that is located on the X chromosome and is responsible for the production of the DRB1 antigen. HLA-DRB1 is a key component of the immune system and plays a crucial role in the regulation of immune responses. Unfortunately, HLA-DRB1 has also been implicated in the development of certain diseases, including cancer. As a result, HLA-DRB1 has become a drug target of interest for researchers and pharmaceutical companies.

HLA-DRB1 is a transmembrane protein that consists of a pre-尾 chain and a post-尾 chain. The pre-尾 chain consists of the constant region, which is responsible for maintaining the structural integrity of the protein, while the post-尾 chain consists of the variable regions, which are responsible for the recognition of foreign antigens by the immune system.

HLA-DRB1 is a key regulator of immune responses and is involved in the development and regulation of CD4+ and CD8+ T cells. CD4+ T cells are responsible for cell-mediated immunity, while CD8+ T cells are responsible for cell-mediated immunity and for the regulation of inflammation. HLA-DRB1 is required for the development and function of CD4+ T cells and is also involved in the regulation of CD8+ T cell responses.

HLA-DRB1 has also been implicated in the development of certain diseases, including cancer. For example, studies have shown that HLA-DRB1 is often expressed in tissues from patients with melanoma, a type of skin cancer. Additionally, HLA-DRB1 has been shown to be involved in the regulation of immune responses in individuals with autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis.

As a result, HLA-DRB1 has become a drug target of interest for researchers and pharmaceutical companies because of its involvement in the immune system and its potential role in the development of certain diseases. HLA-DRB1 has also been shown to be a potential biomarker for certain diseases, such as cancer.

HLA-DRB1 has also been the focus of research into the use of drugs that target the protein. For example, a drug called BK-421 has been shown to inhibit the activity of HLA-DRB1 and has been shown to have potential as a treatment for certain diseases. Additionally, a drug called Oprozomib has been shown to inhibit the activity of HLA-DRB1 and has been shown to have potential as a treatment for certain diseases.

In conclusion, HLA-DRB1 is a human leukocyte antigen that is located on the X chromosome and is responsible for the production of the DRB1 antigen. HLA-DRB1 is a key component of the immune system and plays a crucial role in the regulation of immune responses. Its involvement in the development of certain diseases, including cancer, has made it a drug target of interest for researchers and pharmaceutical companies. Additionally, HLA-DRB1 has also been shown to be a potential biomarker for certain diseases. Further research is needed to fully understand the role of HLA-DRB1 in the immune system and its potential as a drug target.

Protein Name: Major Histocompatibility Complex, Class II, DR Beta 1

Functions: A beta chain of antigen-presenting major histocompatibility complex class II (MHCII) molecule. In complex with the alpha chain HLA-DRA, displays antigenic peptides on professional antigen presenting cells (APCs) for recognition by alpha-beta T cell receptor (TCR) on HLA-DRB1-restricted CD4-positive T cells. This guides antigen-specific T-helper effector functions, both antibody-mediated immune response and macrophage activation, to ultimately eliminate the infectious agents and transformed cells (PubMed:29884618, PubMed:22327072, PubMed:27591323, PubMed:8642306, PubMed:15265931, PubMed:31495665, PubMed:16148104). Typically presents extracellular peptide antigens of 10 to 30 amino acids that arise from proteolysis of endocytosed antigens in lysosomes (PubMed:8145819). In the tumor microenvironment, presents antigenic peptides that are primarily generated in tumor-resident APCs likely via phagocytosis of apoptotic tumor cells or macropinocytosis of secreted tumor proteins (PubMed:31495665). Presents peptides derived from intracellular proteins that are trapped in autolysosomes after macroautophagy, a mechanism especially relevant for T cell selection in the thymus and central immune tolerance (PubMed:17182262, PubMed:23783831). The selection of the immunodominant epitopes follows two processing modes: 'bind first, cut/trim later' for pathogen-derived antigenic peptides and 'cut first, bind later' for autoantigens/self-peptides (PubMed:25413013). The anchor residue at position 1 of the peptide N-terminus, usually a large hydrophobic residue, is essential for high affinity interaction with MHCII molecules (PubMed:8145819)

More Common Targets